If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | ||
![]() British Journal of DermatologyVolume 145 Issue 1, Pages 28 - 31 Published Online: 23 Dec 2001 Journal compilation © 2010 British Association of Dermatologists An Official Journal of the British Association of Dermatologists
Abstract | References | Full Text: HTML, PDF (Size: 293K) | Related Articles | Citation Tracking A retrospective analysis of contact allergy to lanolin Copyright British Association of Dermatologists KEYWORDS allergic contact dermatitis • cosmetic allergy • lanolin • patch testing • wool alcohols ABSTRACT
Background Lanolin is often stated to be an important sensitizer but some of the available literature is based on the analysis of high-risk patients.Objectives To analyse the frequency of contact allergy to lanolin (wool alcohols) in a central London teaching hospital patch-test population.Methods Review of 24,449 patients recorded on our database during 1982–96 who were tested with a standard series containing 30% wool alcohols.Results The mean annual rate of sensitivity to this allergen was 1·7%. The wool alcohols-allergic group contained a higher proportion of females (P < 0·05), and the mean age of both males and females (48·4 and 49·2 years) was higher than that of non-wool alcohols-allergic patients (41·4 and 35·9 years; P < 0·0005). There was no difference in atopic eczema status between these groups. The highest prevalence of allergy to wool alcohols was among patients with lower leg dermatitis (6·0%; 95% confidence interval, CI 4·46–7·54), followed by those with anogenital dermatitis (3·23%; 95% CI 1·81–4·65). There was an unexplained decline in the rate of positive patch tests to Amerchol Accepted for publication 23 February 2001 |